Divalent metal transporter 1 (DMT1), expressed in many different tissues, is responsible for the transport of a broad range of divalent metal ions. DMT1 exists in at least, four distinct isoforms which differ in both the C-terminus (termed here (-)IRE and (+)IRE) and the N-terminus (transcription proceeds from two different promoters). In the rat, two of the forms possess an additional 31 amino acids in the N-terminus (termed exon 1A) whereas the shorter forms lack this sequence (termed exon 2). Studies were performed to compare differences in expression and localization of these isoforms in low density and confluent cultures of rat astrocytes obtained from traumatized striatum and in rat C6 astrocytoma and human U87 glioblastoma. Results of these experiments reveal the presence of both the (+/-)IRE forms of DMT1 in all cultured cells examined. Western blots using affinity purified antibodies, which differentially recognize the two C-terminal species of DMT1, indicate a strong upregulation of the (+)IRE form in low density astrocyte cultures when compared to confluent cultures. Previously we reported that the (-)IRE form was present in both the nucleus and cytoplasm in neurons and neuronal like cells whereas the (+)IRE form was exclusively cytoplasmic. Similar results were found with the (-)IRE species in astrocytes and astrocytomas, i.e. nuclear and cytoplasmic distribution. This form of DMT1 also colocalizes with the early endosomal marker, EEA, suggesting that (-)IRE species may function in the transport of divalent metals. In contrast to our previous findings, however, the (+)IRE form was found predominantly localized in nucleus in both the primary and neoplastic glial cells. Interestingly, neither form of DMT1 colocalizes with the transferrin receptor. These data suggest that selective compartmentalization of specific isoforms of DMT1 imparts distinct and specialized functions that meet the changing needs of essential divalent transition metals as cofactors within cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.molbrainres.2003.11.023 | DOI Listing |
World J Surg Oncol
December 2024
Hepatobiliary and Pancreatic Intervention Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Background: At present, the main clinical application of local ablation therapy, such as radiofrequency ablation (RFA), is to heat the tissue to a certain temperature. However, high temperature will cause thermal damage. Irreversible electroporation (IRE) is a novel minimally invasive local ablation technology for tumors.
View Article and Find Full Text PDFTransl Cancer Res
November 2024
Department of Urology, Yale School of Medicine, New Haven, CT, USA.
Radiation- (radio-)recurrent prostate cancer poses a significant challenge in clinical management due to its complexity and varied treatment responses. The recurrence of prostate cancer following radiotherapy necessitates a nuanced management strategy that considers disease stage and aggressiveness, patient health status, and prior treatment modalities. Androgen deprivation therapy (ADT), a cornerstone in the management of regional or distant relapse, often initiates the therapeutic cascade, effectively suppressing tumor growth by targeting androgen signaling.
View Article and Find Full Text PDFTransl Cancer Res
November 2024
Section of Urology, Department of Surgery, University of Chicago, Chicago, IL, USA.
Background And Objective: The role of focal therapy in the treatment of localized prostate cancer is evolving. However, despite accumulating evidence, current guidelines and regulatory bodies refrain from endorsing focal therapy outside of clinical trials. Our goal was the to review the focal therapy realm for ongoing clinical trials and high impact recently published trials.
View Article and Find Full Text PDFTransl Androl Urol
September 2024
Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ann Transl Med
August 2024
Department of Radiological Sciences, University of California Irvine, Irvine, CA, USA.
Background And Objective: Pancreatic ductal adenocarcinoma (PDAC) is 3 most lethal cancer in the USA leading to a median survival of six months and less than 5% 5-year overall survival (OS). As the only potentially curative treatment, surgical resection is not suitable for up to 90% of the patients with PDAC due to late diagnosis. Highly fibrotic PDAC with an immunosuppressive tumor microenvironment restricts cytotoxic T lymphocyte (CTL) infiltration and functions causing limited success with systemic therapies like dendritic cell (DC)-based immunotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!